Clinical and Experimental Medicine

, Volume 19, Issue 1, pp 149–157 | Cite as

Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer

  • Xifeng Xu
  • Qiong Wu
  • Zhen Wang
  • Song ZhengEmail author
  • Ke Ge
  • Changku Jia
Original Article


The study aimed to evaluate the effectiveness of the first-line chemotherapy FOLFIRINOX in treating pancreatic cancer. Pertinent studies were derived from the PubMed, Cochrane Library and EMBASE. The outcomes were analyzed according to resection rate and radical (R0) resection rate. Data were expressed as weighted commix proportions with 95% confidence intervals (CIs). Twenty-three studies, involving 968 patients with locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC), were examined. After treatment, 55% (95% CI 52–58%) of the patients underwent resection and 40% (95% CI 37–43%) underwent R0 resection, and the median overall survival ranged from 15.5 to 35.4 months, with a 10.0–27.1 months’ median progression-free survival. The meta-analysis shows that FOLFIRINOX, as the first-line therapy, has significant down-staging effects in patients with LAPC or BRPC, with a 40% R0 resection rate and the adverse events under control.


Pancreatic cancer FOLFIRINOX Resection 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefGoogle Scholar
  3. 3.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.CrossRefGoogle Scholar
  4. 4.
    Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.CrossRefGoogle Scholar
  5. 5.
    Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168–75.CrossRefGoogle Scholar
  6. 6.
    Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.CrossRefGoogle Scholar
  7. 7.
    Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: clinical and experimental studies. World J Gastroenterol. 2016;22:776–89.CrossRefGoogle Scholar
  8. 8.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefGoogle Scholar
  9. 9.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  10. 10.
    Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801–10.CrossRefGoogle Scholar
  11. 11.
    Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.CrossRefGoogle Scholar
  12. 12.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefGoogle Scholar
  13. 13.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefGoogle Scholar
  14. 14.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefGoogle Scholar
  15. 15.
    Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.CrossRefGoogle Scholar
  16. 16.
    Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Jop. 2012;13:497–501.Google Scholar
  17. 17.
    Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–5.CrossRefGoogle Scholar
  18. 18.
    Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236–41.CrossRefGoogle Scholar
  19. 19.
    Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–8.CrossRefGoogle Scholar
  20. 20.
    Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol. 2013;52:1231–3.CrossRefGoogle Scholar
  21. 21.
    Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30:361.CrossRefGoogle Scholar
  22. 22.
    Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13:232–8.CrossRefGoogle Scholar
  23. 23.
    Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, et al. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93:e198.CrossRefGoogle Scholar
  24. 24.
    Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–74.CrossRefGoogle Scholar
  25. 25.
    Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-Bonilla A, Velez M, et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015;15:667–73.CrossRefGoogle Scholar
  26. 26.
    Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295–301.CrossRefGoogle Scholar
  27. 27.
    Sadot E, Doussot A, O’Reilly EM, Lowery MA, Goodman KA, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:3512–21.CrossRefGoogle Scholar
  28. 28.
    Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153–9.CrossRefGoogle Scholar
  29. 29.
    Bai X, Su R, Ma T, Shen S, Li G, et al. Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China. Zhonghua Wai Ke Za Zhi. 2016;54:270–5.Google Scholar
  30. 30.
    Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:809–12.CrossRefGoogle Scholar
  31. 31.
    Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, et al. Locally Advanced Pancreatic Cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann Surg. 2016;264:457–63.CrossRefGoogle Scholar
  32. 32.
    Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151:e161137.CrossRefGoogle Scholar
  33. 33.
    Okada KI, Kawai M, Hirono S, Satoi S, Yanagimoto H, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016;78:719–26.CrossRefGoogle Scholar
  34. 34.
    Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2017.Google Scholar
  35. 35.
    Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8:46337–47.Google Scholar
  36. 36.
    Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. Jop. 2018;19:75–85.Google Scholar
  37. 37.
    Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963–9.CrossRefGoogle Scholar
  38. 38.
    Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer. 2007;110:738–44.CrossRefGoogle Scholar
  39. 39.
    Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRefGoogle Scholar
  40. 40.
    Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.CrossRefGoogle Scholar
  41. 41.
    Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014;2:CD010244.Google Scholar
  42. 42.
    Assifi MM, Lu X, Eibl G, Reber HA, Li G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–73.CrossRefGoogle Scholar
  43. 43.
    Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.CrossRefGoogle Scholar
  44. 44.
    Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.CrossRefGoogle Scholar
  45. 45.
    Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.CrossRefGoogle Scholar
  46. 46.
    Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33:1770–8.CrossRefGoogle Scholar
  47. 47.
    Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44:515–21.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Medical Oncology, Hangzhou First People’s HospitalNanjing Medical UniversityHangzhouChina
  2. 2.Department of Hepatobiliary SurgeryHangzhou First People’s HospitalHangzhouChina
  3. 3.Department of Medical Oncology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou Cancer HospitalZhejiang Chinese Medical University Affiliated Hangzhou First HospitalHangzhouChina

Personalised recommendations